Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach.
Front Immunol
January 2025
Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Human rhinovirus C (HRV-C) is a significant contributor to respiratory tract infections in children and is implicated in asthma exacerbations across all age groups. Despite its impact, there is currently no licensed vaccine available for HRV-C. Here, we present a novel approach to address this gap by employing immunoinformatics techniques for the design of a multi-epitope-based vaccine against HRV-C.
View Article and Find Full Text PDFAssessment of heat-killed expressing Chikungunya virus E2 protein as a candidate vaccine for dual protection against Chikungunya virus and .
Front Immunol
January 2025
Nanobioscience Group, Agharkar Research Institute, Pune, India.
The Chikungunya virus (CHIKV) is a mosquito-borne virus with a long history of recurring epidemics transmitted through mosquitoes. The rapid spread of CHIKV has intensified the need for potent vaccines. Escherichia coli (), a vital part of human gut microbiota, is utilized in recombinant DNA technology for cloning.
View Article and Find Full Text PDFDevelopment of an attenuated glutamine synthetase (GS) selection system for the stable expression of tissue plasminogen activator in CHO-K1 cells.
Prep Biochem Biotechnol
January 2025
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Chinese hamster ovary (CHO) cells represent the most common host system for the expression of high-quality recombinant proteins. The development of stable CHO cell lines used in industrial recombinant protein production often relies on dihydrofolate reductase (DHFR) and glutamine synthetase (GS) amplification systems. Conventional approaches to develop stable cell lines lead to heterogeneous cell populations.
View Article and Find Full Text PDFProteomics Reveals Distinctive Host Cell Protein Expression Patterns in Fed-Batch and Perfusion Cell Culture Processes.
Biotechnol J
January 2025
Biologics Process Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Chinese hamster ovary (CHO) cells are widely used to produce recombinant proteins, including monoclonal antibodies (mAbs), through various process modes. While fed-batch (FB) processes have been the standard, a shift toward high-density perfusion processes is being driven by increased productivity, flexible facility footprints, and lower costs. Ensuring the clearance of process-related impurities, such as host cell proteins (HCPs), is crucial in biologics manufacturing.
View Article and Find Full Text PDFImpact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.
Ann Hematol
January 2025
Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy.
Calreticulin (CALR) mutations are detected in around 20% of patients with primary and post-essential thrombocythemia myelofibrosis (MF). Regardless of driver mutations, patients with splenomegaly and symptoms are generally treated with JAK2-inhibitors, most commonly ruxolitinib. Recently, new therapies specifically targeting the CALR mutant clone have entered clinical investigation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!